This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.
LLY Down as Patients Regain Weight After Stopping Zepbound
by Zacks Equity Research
Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate
by Zacks Equity Research
Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
The Zacks Analyst Blog Highlights Alphabet, NVIDIA, Roche, Intuit and AT&T
by Zacks Equity Research
Alphabet, NVIDIA, Roche, Intuit and AT&T are included in this Analyst Blog.
Top Research Reports for Alphabet, NVIDIA & Roche
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), NVIDIA Corporation (NVDA) and Roche Holding AG (RHHBY).
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
by Zacks Equity Research
Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.
Small-Cap Russell Leads the Way, Jobs Data to Come
by Mark Vickery
Only the small-cap Russell 2000 managed to stay above zero the entire trading day.
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
by Zacks Equity Research
Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
by Zacks Equity Research
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.
Here's Why You May Invest in Puma Biotechnology (PBYI) Stock
by Zacks Equity Research
Here, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever.
Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market
by Zacks Equity Research
Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
by Zacks Equity Research
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
Roche (RHHBY) Tecentriq SC Receives Positive CHMP Opinion
by Zacks Equity Research
Roche's (RHHBY) subcutaneous (SC) formulation of immuno-oncology drug Tecentriq gets CHMP's positive recommendation for all approved indications.
Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.
Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.
Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.
Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike
by Zacks Equity Research
Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.
Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.
Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.
Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat
by Zacks Equity Research
Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.